Clinical Trial Update: Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the effect of QVA149 (indacaterol/glycopyrronium) on exercise tolerance in chronic obstructive pulmonary disease; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium) (indacaterol/glycopyrronium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 3 | Status: COMPLETED | Results posted: 2013-03-20